Core-Binding Factor Leukemia Hijacks the T Cell–Prone PU.1 Antisense Promoter

Researchers showed that transcriptional downregulation of PU.1 was an active process involving an alternative promoter in intron 3 that was induced by RUNX transcription factors driving noncoding antisense transcription.
[Blood]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Lava Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

LAVA Therapeutics N.V. announced that the US FDA has granted orphan drug designation for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.
[LAVA Therapeutics N.V.]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Dynamic Changes in tRNA Modifications and Abundance during T Cell Activation

Scientists examined the tRNA and mRNA pools of T cells during their vigorous proliferation and differentiation upon triggering their antigen receptor.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Adoptive CD8+T-Cell Grafted with Liposomal Immunotherapy Drugs to Counteract the Immune Suppressive Tumor Microenvironment and Enhance Therapy for Melanoma

The immunosuppressive tumor microenvironment has become a formidable obstacle to the treatment of tumors using adoptive T cell therapy, in particular solid tumors. Effector OT-1 CD8+T cells conjugated with liposomal immune regulators were developed to address this issue.
[Nanoscale]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Alloantigen-Activated (AAA) CD4+ T Cells Reinvigorate Host Endogenous T Cell Immunity to Eliminate Pre-established Tumors in Mice

Alloantigen-activated CD4+ T cells were generated from CD4+ T cells isolated from BALB/c mice in cultures with dendritic cells induced from C57BL/6 mice.
[Journal of Experimental & Clinical Cancer Research]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Therapeutically Expanded Human Regulatory T-cells Are Super-Suppressive Due to HIF1A Induced Expression of CD73

Scientists demonstrated that expanded human Tregs switch their metabolism to aerobic glycolysis and show enhanced suppressive function through hypoxia-inducible factor 1-alpha driven acquisition of CD73 expression.
[Communications Biology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Modular Self-Assembly System for Development of Oligomeric, Highly Internalizing and Potent Cytotoxic Conjugates Targeting Fibroblast Growth Factor Receptors

Researchers aimed to develop a modular, self-assembly system for generation of oligomeric cytotoxic conjugates, capable of FGFR1 clustering, for targeting FGFR1-overproducing cancer cells.
[Journal of Biomedical Science]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors

Immune-Onc Therapeutics, Inc. announced that the first patient has been dosed in the company’s first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) for the treatment of solid tumors.
[Immune-Onc Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Signatures of Plasticity, Metastasis, and Immunosuppression in an Atlas of Human Small Cell Lung Cancer

Scientists sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 small cell lung cancer (SCLC) transcriptomes. They observed greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes.
[Cancer Cell]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Smart Immune Receives IRB Approval for Phase I/II Clinical Trial of Proprietary Allogeneic T-Cell Product Smart-101 (ProTcell™) for AML and ALL

Smart Immune SAS, a T cell medicine company utilizing its proprietary ex vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell progenitors Smart101 for rapid immune reconstitution, announced that the institutional review board (IRB) of the Memorial Sloan Kettering Cancer Center has approved the commencement of the company’s Phase I/II clinical trial.
[Smart Immune SAS]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Homeostatic Cytokines Tune Naivety and Stemness of Cord Blood-Derived Transgenic T Cells

Investigators proposed an optimized process using cord blood to generate minimally differentiated T-cell products in terms of phenotype, function, gene expression, and metabolism, using peripheral blood-derived T cells cultured with IL-2 as a standard.
[Cancer Gene Therapy]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share